However, the mast cell tryptase
is also elevated in systemic mastocytosis, and although this condition may be manifest by skin pigmentation, unexplained diarrhoea or abdominal pain, or musculoskeletal pain or episodes of hypotension, it may be previously unsuspected, as in this case.
Celera has solved the crystal structures of both Factor VIIa and tryptase
in the presence of small molecule inhibitors.
The Schwann cell markers, S100 protein, and 2'2'-cyclic nucleotide 3' phosphodiesterase (CNPase), the neuronal markers synaptophysin, neuron-specific enolase (NSE), and mast cell tryptase
expression, was determined by incubation overnight at 4 [degrees] C with commercially available primary antibody, followed by incubation with appropriate biotinylated secondary antibody (Dako, Glostrup, Denmark) and strepABCcomplex or ABCcomplex (Dako), prepared according to the manufacturer's instructions.
While various preclinical small molecule programs have continued to move forward, toxicology and safety evaluations of the lead tryptase
inhibitor for asthma originally planned for the recent quarter were not undertaken.
Celera Genomics intends to advance its most promising small molecule compounds, such as tryptase
inhibitors for asthma and allergic rhinitis and its Factor VIIa inhibitors for anticoagulation, forward into clinical development.
Celera Genomics intends to advance its most advanced small molecules programs, such as its Factor VIIa inhibitors for anticoagulation and tryptase
inhibitors for asthma and allergic rhinitis, into clinical trials on its own account.
In October 2002, Celera Genomics purchased a number of pre-clinical oral tryptase
inhibitors for the treatment of asthma from Bayer AG.
Axys said it does not expect to incur further development expense for the compound and is concentrating on the oral tryptase
program with Bayer.
Like the Delta technology, which remains the basis for oral inhibitors of tryptase
under preclinical study by Bayer AG, the new scaffold design paradigm yields inhibitors that are non-peptide, not dependent on chiral centers for activity, and have low molecular weights.
Nasdaq:AXPH) today announced a newly amended agreement with Bayer AG of Leverkusen, Germany that provides Axys exclusive rights to develop a specific tryptase
inhibitor, APC 2059, as a potential inhaled therapy for asthma and as an injectable treatment for ulcerative colitis.
APC 2059 is a small molecule tryptase
inhibitor that was delivered in this study by subcutaneous injection.